Revenue segments as reported by the company.

Pharmaceutical

Animal Health

Other Revenues

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Selling, general and administrative

Research and development

Restructuring costs

Other (income) expense, net

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Merck

Merck & Co., Inc. engages in the provision of health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products. It operates through the following segments: Pharmaceutical, Animal Health, and Other. The Pharmaceutical segment includes human health pharmaceutical and vaccine products. The Animal Health segment discovers, develops, manufactures, and markets animal health products, such as pharmaceutical and vaccine products, for the prevention, treatment and control of disease in livestock and companion animal species. The Other segment consists of sales for the non-reportable segments of healthcare services. The company was founded in 1891 and is headquartered in Kenilworth, NJ.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Merck reports robust Q4 earnings, eyes growth through innovation

Merck's Q4 2022 performance reflects strong revenue growth and strategic advancements across key therapeutic areas, positioning the company for future success.
While facing challenges such as patent estate concerns and competitive pressures, Merck's focus on innovation and partnerships presents opportunities for sustained growth.
Analyst inquiries and executive responses during the earnings call highlight the company's commitment to transparency, patient outcomes, and shareholder value.

Merck reports robust Q1 earnings, eyes growth in oncology and vaccines

Merck's Q1 performance reflects strong revenue growth driven by oncology and vaccines, with a raised full-year guidance and focus on pipeline advancements.
The company's strategic strengths lie in its focus on compelling science, value alignment in business decisions, and commitment to innovation.
Challenges include potential impacts of EU legislation, post-KEYTRUDA LOE growth strategies, and navigating regulatory complexities for new treatments.
Opportunities in expansion in China, revenue diversification, innovative combination therapies, and protective treatment strategies position Merck for future growth.

Merck reports robust Q2 earnings, focuses on growth opportunities

Merck's Q2 performance showcased strong earnings driven by Oncology and Vaccines growth
Despite challenges like regulatory concerns and price pressures, the company remains focused on innovation
Opportunities lie in expanding KEYTRUDA's reach in cancer indications and advancing in immunology
Overall, Merck's strategic acquisitions and commitment to growth position it well for the future

Merck reports robust Q3 earnings, eyes growth in precision medicine

Merck's Q3 2023 Earnings Call highlighted strong revenue growth, pipeline advancements, and increased full-year revenue guidance. The company's strategic focus on key therapeutic areas and precision medicine approaches positions it for continued success and innovation.

Merck reports robust Q4 earnings, eyes growth through strategic investments

Merck's strong Q4 performance was driven by KEYTRUDA and Vaccines, with positive revenue guidance for 2024. The company remains focused on R&D advancements, strategic investments, and shareholder value. Challenges include managing expenses and maximizing market opportunities.

Merck reports robust Q1 earnings, eyes growth in innovative treatments

Merck's Q1 performance reflects strong revenue growth, operational efficiency, and a positive outlook for future earnings.
The company's focus on innovation, strategic investments, and commitment to patient access position it well for long-term success.
Challenges in pipeline differentiation and market competition require continued strategic planning and differentiation strategies.
Opportunities in new treatment areas, market expansion, and upcoming events offer avenues for sustained growth and market leadership.

Merck reports robust Q2 earnings, eyes future drug launches

Merck's Q2 earnings call highlighted strong financial performance, innovative product launches, and confidence in future growth. The company addressed analyst inquiries, emphasizing long-term pipeline growth and short-term financial guidance while expressing gratitude for investor support.

Merck reports solid Q3 earnings, eyes growth through diversification

Merck's Q3 2024 performance reflects revenue growth driven by key products and clinical advancements, despite regional sales variations and inventory challenges.
The company's strengths in diversification, clinical progress, and strategic investments position it well for future growth and competitive edge in the market.
While facing challenges in specific product sales and clinical trials, Merck has opportunities to capitalize on its strengths, expand offerings, and drive sustained growth.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Merck & Co., Inc. is a health care company, which engages in the provision of health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products. It operates through the following segments: Pharmaceutical, Animal Health, and Other. The Pharmaceutical segment includes human health pharmaceutical and vaccine products. The Animal Health segment discovers, develops, manufactures, and markets animal health products, such as pharmaceutical and vaccine products, for the prevention, treatment and control of disease in livestock, and companion animal species. The Other segment consists of sales for the non-reportable segments of healthcare services. The company was founded in 1891 and is headquartered in Rahway, NJ.

Pandion Therapeutics Holdco LLC

Merck & Co. announced an agreement Thursday to buy Pandion Therapeutics Inc. in a deal valued at $1.85 billion. Under terms of the deal, Merck will pay $60 in cash for each Pandion share outstanding, which represents a 134.1% premium to Wednesday's closing price.

Merck to buy Pandion Therapeutics for 134% premium

KENILWORTH, N.J & WATERTOWN, Mass.--(BUSINESS WIRE)---- $MRK #MRK--Merck to Acquire Pandion Therapeutics

Merck to Acquire Pandion Therapeutics

KENILWORTH, N.J.--(BUSINESS WIRE)---- $MRK #MRK--Merck to Present at the Cowen 41st Annual Health Care Conference

Merck to Present at the Cowen 41st Annual Health Care Conference

Johnson & Johnson

Eli Lilly

Pfizer

Even investors that don't own the stocks must have had their interest piqued about the goings-on with GameStop Corp. (NYSE:GME), AMC Entertainment Holdings Inc. (NYSE:AMC) and Express Inc. (NYSE:EXPR). The companies were involved in a "short squeeze" that saw the shares of all three struggling companies gyrating wildly.

Big Pharma Short Percentage Is Below Overall Market

AbbVie

Bristol-Myers

Kroger

GuruFocus is proud to announce that there were three winners of the fourth-quarter Warren Buffett (Trades, Portfolio) contest: Richday101, Chihin and Nicola Guida. Richday101 and Chihin guessed correctly that Buffett (or Ted Weschler, or Todd Combs) purchased AbbVie Inc. (NYSE:ABBV), Merck & Co. Inc. (NYSE:MRK) and Bristol-Myers Squibb Co. (NYSE:BMY).

GuruFocus Announces 3 Winners of 4th-Quarter Warren Buffett Contest

The FDA doesn't think too highly of the big drugmaker's submission for a new indication for Keytruda.

Did Merck Make a Mistake With a Key FDA Filing?

Fitbit

Gildan Activewear

NetEase

Prem Watsa (Trades, Portfolio), the founder and chairman of Fairfax Financial Ltd. (TSX:FFH), disclosed this week that his insurance company's top five trades during the fourth quarter featured new positions in Pfizer Inc. (NYSE:PFE) and Merck & Co. (NYSE:MRK) and the closure of his holdings in Fitbit Inc. (NYSE:FIT), Gildan Activewear Inc. (NYSE:GIL) and NetEase Inc. (NASDAQ:NTES).

Prem Watsa's Top 5 Trades of the 4th Quarter

Apple

Barrick Gold

Verizon

Verizon Communications Inc 5.9 % Notes 2014-15.2.54 Sr

Berkshire Hathaway's (NYSE:BRK.A) (NYSE:BRK.B) latest 13F report was filed last night. The report detailed the conglomerate's equity positions at the end of December 2020.

Buffett's Berkshire Buys Oil, Heathcare and Telecoms in 4th Quarter

AstraZeneca

Based on the planned interim analysis, the Independent Data Monitoring Committee (IDMC) has recommended that OlympiA Phase 3 trial evaluating AstraZeneca Plc (NASDAQ: AZN) and Merck & Co Inc's (NYSE: MRK) Lynparza (olaparib) will move to early primary analysis and reporting. According to IDMC, the trial crossed the superiority boundary for its primary endpoint of invasive disease-free survival (iDFS).

AstraZeneca/Merck's PARP Inhibitor In Late-Stage Breast Cancer Study To Enter Early Analysis

These two pharma giants' recent struggles in the stock market represent a buying opportunity.

2 Top Stocks to Buy for a Post-Pandemic World

KENILWORTH, N.J.--(BUSINESS WIRE)---- $MRK #MRK--Independent Data Monitoring Committee Concludes OlympiA Trial of LYNPARZA Crossed Superiority Boundary of Invasive Disease-Free Survival vs. Placebo

Independent Data Monitoring Committee Concludes OlympiA Trial of LYNPARZA® (olaparib) Crossed Superiority Boundary for Invasive Disease-Free Survival vs. Placebo at Planned Interim Analysis

Berkshire Hathaway disclosed fourth-quarter buys of Merck, Bristol-Myers, and AbbVie, while exiting Pfizer.

Warren Buffett's Berkshire Hathaway Traded Stock in Pharma, Banks

Chevron

Suncor Energy

T-Mobile US

Wells Fargo

Warren Buffett's Berkshire Hathaway Inc. BRK.ABRK.B loaded up on drug, telecom and oil stocks while trimming its position in Apple Inc. AAPL over the past quarter, according to a Securities and Exchange Commission filing late Tuesday. Berkshire increased its stake in Abbvie Inc. ABBV by 20%, Bristol-Myers Squibb Co. BMY by 11%, and Merck & Co. MRK by 28%.

Berkshire Hathaway ups drug-stock stakes while trimming Apple

Merck & Co Inc (NYSE: MRK) and Eisai Co Ltd (OCTMKT: ESALY) unveiled new data from the Phase 3 CLEAR study (KEYNOTE-581/Study 307) evaluating a combo of Merck's Keytruda and Eisai's Lenvima (lenvatinib) or Lenvima plus chemotherapy everolimus against Pfizer Inc's (NYSE: PFE) Sutent (sunitinib) for the first-line treatment of advanced renal cell carcinoma. The companies presented the data at the American Society of Clinical Oncology's Genitourinary Cancers Symposium.

Merck/Eisai's Keytruda-Lenvima Combo Tops Standard Of Care In Late-Stage Kidney Cancer Study

Baxter

Cigna

Cisco Systems

Home Depot

McDonald's

Mondelez

Procter & Gamble

Raytheon Technologies

UnitedHealth Group

Exxon Mobil

31 Of 50 Stocks Billionaires Best Love Pay Dividends As Of February

Anthem

Humana

Vertex Pharmaceuticals

With the markets setting all-time highs again and the first quarter soon to begin winding down, investors may be pondering how to position themselves for the rest of the year.

5 Health Care Laggards With Healthy Upside Potential

Aflac

CNA Financial

Fidelity National Financial

Prudential Financial

When we find cash flow machines like the eight dividend payers we're about to discuss, we're talking about decades of payments.

8 Rising Dividends To Buy And Hold For Decades

KENILWORTH, N.J. & WOODCLIFF LAKE, N.J.--(BUSINESS WIRE)---- $MRK #MRK--KEYTRUDA Plus LENVIMA Demonstrated Superior PFS and OS Versus Sunitinib as First-Line Treatment for Patients With Advanced Renal Cell Carcinoma

KEYTRUDA® (pembrolizumab) Plus LENVIMA® (lenvatinib) Demonstrated Superior Progression-Free Survival (PFS) and Overall Survival (OS) Versus Sunitinib as First-Line Treatment for Patients With Advanced Renal Cell Carcinoma

Merck is a global healthcare company with a strategic focus on its fast-growing oncology and vaccine businesses. A $9 billion special dividend from the Organon spinoff will fund additional R&D efforts and business development activities.

Merck: Positioned To Deliver For Dividend Investors In 2021

Merck stock fell in February after the company issued a disappointing fourth-quarter report on the heels of its decision to scrap two coronavirus vaccines. Is Merck stock a buy?

Merck Says Covid Hammered 2020 Sales By $2.5 Billion — Is Merck Stock A Buy?

Medtronic

The Vanguard Health Care Fund (Trades, Portfolio) sold shares of the following stocks during the fourth quarter, which ended on Dec. 31.

The Vanguard Health Care Fund Exits Medtronic, Merck & Co

We think that Merck Inc. currently is a better pick compared to Johnson & Johnson. MRK stock trades at about 4x trailing revenues, compared to around 5.4x for JNJ.

Here's Why Merck Is A Better Pick Over Johnson & Johnson Stock

According to the Wall Street Journal, Merck & Co Inc (NYSE: MRK) is reportedly in talks with governments and companies to potentially help with the manufacturing of COVID-19 vaccines that have already been authorized. The supply of COVID-19 shots remains limited, prompting the vaccine-makers such as Pfizer Inc (NYSE: PFE) and BioNTech SE (NASDAQ: BNTX) to team up with other companies to fill the gap.

Merck In Talks To Possibly Produce COVID-19 Shots: WSJ

Roche Holding AG

The Vanguard Health Care Fund (Trades, Portfolio) has released its portfolio for the fourth quarter. Major trades include selling out of Medtronic PLC (NYSE:MDT), Merck & Co Inc. (NYSE:MRK) and Roche Holding AG (XSWX:ROG).

The Vanguard Health Care Fund's Top 5 Trades of the 4th Quarter

Merck & Co Inc (NYSE: MRK) isn't likely to win the FDA go-ahead for Keytruda's use in pre and post-surgery triple-negative breast cancer anytime soon.  The FDA advisory committee voted unanimously to recommend deferral of a regulatory decision on Keytruda (pembrolizumab) to treat patients with high-risk, early-stage triple-negative breast cancer.

News for Merck Stock (MRK)